Please assess the completion status of the following clinical trial:

Trial Title: The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed renal cell carcinoma that is metastatic or unresectable.~* If patients have measurable disease restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology.~* Patients must provide access to tissue blocks containing adequate tumor for interpretation and analysis.~* Patients must have measurable disease.~* Patients must have good performance status (ECOG 0 or 1; Karnofsky PS 100-80%).~* Patients must have adequate organ function.~* Patients must have no contraindication of vasopressor agents.~* Patients must be ≥ 18 years of age.~Exclusion Criteria:~* Patients who have received systemic therapy for metastatic disease.~* Patients with organ allografts.~* Patients who require or are likely to require systemic corticosteroid therapy for intercurrent illness.~* Patients with any significant medical disease other than the malignancy (e.g. COPD, patients with ascites or pleural effusions), which in the opinion of the investigator would significantly increase the risk of immunotherapy.~* Patients with a history of another malignancy within the past 5 years other than surgically cured non-melanoma skin cancer, carcinoma-in-situ or Stage I carcinoma of the cervix.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HD IL2 (Type: EXPERIMENTAL): Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).